Please don't take your organs to heaven,heaven knows we need them here
Followers | 517 |
Posts | 102,285 |
Boards Moderated | 2 |
Alias Born | 01/18/2003 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
symbol change in for morrow arbh
🧠#Psycheceutical (OTCPK: $BWVI): Thinking Outside The Brain To Help People #Heal
— Benzinga (@Benzinga) February 28, 2023
Learn more about #psychedelicmedicine company #PsycheceuticalBioscience, their novel medicine, & upcoming #clinicaltrials in this interview!
🧠https://t.co/WNZ0Bf7qeV
🌿 @psycheceutical#ad pic.twitter.com/1DMuDInT7H
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Invest in the growing psychedelics industry and join Strategic Advisor @HarringtonKevin as he moderates the 'Evolution of The Legal Psychedelics Industry' panel & offers his Shark Tank expertise at @kahnerglobal's Cannabis & Psychedelics Investment Summit: https://t.co/TkA7SG5Zek https://t.co/eaphbS1nnu
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
12-22-23 10-11-14
Mornin All~~!!
Psycheceutical ??enters into agreement with iNGENu to conduct ?human ?clinical trials of NeuroDirectâ„¢ ketamine topical ?in Australia
Phase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirectâ„¢ ketamine
Phase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirectâ„¢ ketamine on improving their symptoms
BWVI:
We’re thrilled to announce that we have partnered with iNGENū CRO to design and conduct two clinical trials to evaluate our patented NeuroDirect™ ketamine topical delivery system for treating #PTSD.
— Psycheceutical (@psycheceutical) February 15, 2023
Learn more about today's #clinicaltrials announcement: https://t.co/UjYnWKH87p pic.twitter.com/LZuIvTZp9p
BWVI NEWS: Psycheceutical Bioscience Inc BWVI:OTC Pink - Current Information
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
GlobeNewswire
11:30 AM ET
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSDGlobeNewswireFebruary 15, 2023Psycheceutical â??â??enters into agreement with iNGENÅ« to conduct â??human â??clinical trials of NeuroDirect(TM) ketamine topical â??in AustraliaPhase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect(TM) ketaminePhase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirect(TM) ketamine on improving their symptomsMIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced it has entered into an exclusive agreement with iNGENÅ« Pty Ltd. ("iNGENÅ«"), an Australian-based Contract Research Organization (CR O), to design and conduct two clinical trials to evaluate Psycheceutical's patented NeuroDirect(TM) ketamine topical delivery system.
Psycheceuticalâ??â?? â??is planning to conduct the clinical trials in â??â??Australia. The first in-human, Phase I clinical trial with iNGENÅ« is studying 20 people, each dosed with a single application of NeuroDirect(TM) ketamine. This trial is designed to test the "Safety, Tolerability, and Pharmacokinetics of NeuroDirect Ketamine in Healthy Adult Volunteers."
"We're thrilled to have partnered with iNGENÅ« as we move our proprietary delivery technology into human clin ical trials. iNGENÅ« is an industry-leading, full-service CRO providing end-to-end services for companies like ours developing psychedelic drugs. Together, we're committed to discovering new psychedelic therapies for mental health disorders and central nervous system diseases," said Psycheceutical CEO Chad Harman. "We're eager to engage in this next phase of the development of â??â??â??â??our NeuroDirect(TM) delivery system, which we're designing to solve the issues with side effects that most psychedelic drug development companies face, while at the same time developing lifesaving mental health treatments.â??â??"
â??â??â??The subsequent Phase II clinical trial, also with iNGENÅ«, is targeted to involve 115 participants with PTSD and to analyze the effectiveness of NeuroDirect(TM) ket amine on improving their symptoms. This trial has been designed to be considered for "pivotal clinical trial" recognition by the FDA, which would then allow the Company to proceed directly to a Phase III clinical trial rather than an additional Phase IIb clinical trial, thereby saving the Company significant cost and time.
"Our team is excited to partner with Psycheceutial for their clinical development needs, and we look forward to working together to design and conduct trials with our partners here in Australia," said Dr. Sud Agarwal, CEO of iNGENÅ«. "We're impressed with Psycheceutical's development of psychedelic delivery technologies which potentially offer safer and more effective dosing for patients."
By conducting its clinical trials in Australia, Psycheceutical can take advantage of the Australian federal government's Research & Development Tax Incentive Program, which will provide rebates to the Company of up to 43.5 percent on eligible expenditures for research and development conducted in Australia. "This saves us a considerable amount of capital for the research and development of other novel compounds in our drug pipeline," said Chad Harman, Psycheceutical CEO.
NeuroDirect(TM) for Non-Systemic DeliveryPsycheceutical's NeuroDirect(TM) non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds such as hallucinations, nausea, and dizziness. NeuroDirect(TM) is designed to be administered at home instead of a clinical setting, greatly lowering the cost of care for both insurance companies and patients, increasing access to these life-saving treatments for anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc. Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic industry, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
About iNGENÅ«iNGENÅ« is a globally-focused Contract Research Organization (CRO) working exclusively in the cannabinoid and psychedelic space. The company is a full-service CRO performing clinical trials for US, Canadian, and European sponsors in Australia. iNGENÅ« helps companies access the advantages of conducting clinical trials in Australia, including the ability to perform FDA registration clinical trials prior to opening an IND, access to the lucrative 43.5% research and development rebate from th e Australian government on all research expenses, and rapid start-up of clinical trials in under 12 weeks.
NEWS: Psycheceutical Bioscience Inc BWVI:OTC Pink - Current Information
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
GlobeNewswire
11:30 AM ET
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSDGlobeNewswireFebruary 15, 2023Psycheceutical â??â??enters into agreement with iNGENÅ« to conduct â??human â??clinical trials of NeuroDirect(TM) ketamine topical â??in AustraliaPhase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect(TM) ketaminePhase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirect(TM) ketamine on improving their symptomsMIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced it has entered into an exclusive agreement with iNGENÅ« Pty Ltd. ("iNGENÅ«"), an Australian-based Contract Research Organization (CR O), to design and conduct two clinical trials to evaluate Psycheceutical's patented NeuroDirect(TM) ketamine topical delivery system.
Psycheceuticalâ??â?? â??is planning to conduct the clinical trials in â??â??Australia. The first in-human, Phase I clinical trial with iNGENÅ« is studying 20 people, each dosed with a single application of NeuroDirect(TM) ketamine. This trial is designed to test the "Safety, Tolerability, and Pharmacokinetics of NeuroDirect Ketamine in Healthy Adult Volunteers."
"We're thrilled to have partnered with iNGENÅ« as we move our proprietary delivery technology into human clin ical trials. iNGENÅ« is an industry-leading, full-service CRO providing end-to-end services for companies like ours developing psychedelic drugs. Together, we're committed to discovering new psychedelic therapies for mental health disorders and central nervous system diseases," said Psycheceutical CEO Chad Harman. "We're eager to engage in this next phase of the development of â??â??â??â??our NeuroDirect(TM) delivery system, which we're designing to solve the issues with side effects that most psychedelic drug development companies face, while at the same time developing lifesaving mental health treatments.â??â??"
â??â??â??The subsequent Phase II clinical trial, also with iNGENÅ«, is targeted to involve 115 participants with PTSD and to analyze the effectiveness of NeuroDirect(TM) ket amine on improving their symptoms. This trial has been designed to be considered for "pivotal clinical trial" recognition by the FDA, which would then allow the Company to proceed directly to a Phase III clinical trial rather than an additional Phase IIb clinical trial, thereby saving the Company significant cost and time.
"Our team is excited to partner with Psycheceutial for their clinical development needs, and we look forward to working together to design and conduct trials with our partners here in Australia," said Dr. Sud Agarwal, CEO of iNGENÅ«. "We're impressed with Psycheceutical's development of psychedelic delivery technologies which potentially offer safer and more effective dosing for patients."
By conducting its clinical trials in Australia, Psycheceutical can take advantage of the Australian federal government's Research & Development Tax Incentive Program, which will provide rebates to the Company of up to 43.5 percent on eligible expenditures for research and development conducted in Australia. "This saves us a considerable amount of capital for the research and development of other novel compounds in our drug pipeline," said Chad Harman, Psycheceutical CEO.
NeuroDirect(TM) for Non-Systemic DeliveryPsycheceutical's NeuroDirect(TM) non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds such as hallucinations, nausea, and dizziness. NeuroDirect(TM) is designed to be administered at home instead of a clinical setting, greatly lowering the cost of care for both insurance companies and patients, increasing access to these life-saving treatments for anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc. Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic industry, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
About iNGENÅ«iNGENÅ« is a globally-focused Contract Research Organization (CRO) working exclusively in the cannabinoid and psychedelic space. The company is a full-service CRO performing clinical trials for US, Canadian, and European sponsors in Australia. iNGENÅ« helps companies access the advantages of conducting clinical trials in Australia, including the ability to perform FDA registration clinical trials prior to opening an IND, access to the lucrative 43.5% research and development rebate from th e Australian government on all research expenses, and rapid start-up of clinical trials in under 12 weeks.
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Mornin All~~!!
Yessir ring a ding ding in the morning...Nice
Mornin All~~!!